Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables - Wikidata - awgldk - TriplyDB

Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables

Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables

http://www.wikidata.org/entity/Q33614495

about

Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals The Significance of a Common Idiotype (1F7) on Antibodies against Human Immune Deficiency Virus Type 1 and Hepatitis C Virus Structural insights on the role of antibodies in HIV-1 vaccine and therapy A Blueprint for HIV Vaccine Discovery HIV-1 neutralizing antibodies: understanding nature's pathways Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1 Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing Broad and potent neutralization of HIV-1 by a gp41-specific human antibody Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21 Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies 9G4 autoreactivity is increased in HIV-infected patients and correlates with HIV broadly neutralizing serum activity Viremic HIV infected individuals with high CD4 T cells and functional envelope proteins show anti-gp41 antibodies with unique specificity and function Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development Current views on the potential for development of a HIV vaccine.Coverage of primary mother-to-child HIV transmission isolates by second-generation broadly neutralizing antibodies.Neutralization sensitivity of HIV-1 subtype B' clinical isolates from former plasma donors in China.Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals.Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters.Flow virometry analysis of envelope glycoprotein conformations on individual HIV virions.HIV neutralizing antibodies: clinical correlates and implications for vaccines.Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.Early development of broadly neutralizing antibodies in HIV-1-infected infants Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller Characteristics of the earliest cross-neutralizing antibody response to HIV-1.Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant.Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease.HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1 Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein.Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco.Infection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virus Low-replicating viruses and strong anti-viral immune response associated with prolonged disease control in a superinfected HIV-1 LTNP elite controller Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection HIV p24 as scaffold for presenting conformational HIV Env antigens.

P2860

Q24635002-83164D00-536B-4CE7-92FC-92A9B49E2AD8 Q26767258-7585442F-16BD-4246-B0AD-03014CCB637C Q26829461-14B073D5-0022-4C4E-8BB8-4B8F50C4BEDF Q26829865-E4FFE819-6892-4939-B6D3-29F89C857674 Q27000480-7284B3F5-F7A5-42B3-8724-43640D1FA8D6 Q27644515-50888555-21CE-4C16-9CA3-0CCE385CCF0C Q27662167-51978C0C-5BA6-46B0-ADE1-CF79C3116243 Q27670829-81408AFB-2010-4749-B0DA-AD38141F95ED Q27671696-3D1D6B98-E392-4601-BCB9-AECE7F2AB0F3 Q27675131-7AB61C5F-BF9A-4F7D-8E67-74BFF051BF64 Q27677117-796B7508-D5DE-4F94-9BCD-1CB72B544F8C Q27684578-D3EEC0EF-FB51-40AE-80E8-B5A58545DD9E Q28307312-82DFC75C-B47B-4BA9-8387-8594353BC7FB Q28602877-2BDE9410-231E-4A58-AF5C-73CAC205DE06 Q28730532-43948489-7491-42C6-AE3B-D908E9C20D82 Q28732293-CF6D8FD0-1A64-4BFF-9401-7B53716144C6 Q29619511-83276E6E-160D-4218-85EE-6A7AE5ADB8B0 Q30355260-0F74E04D-1D38-433A-9491-B47ABB6F38B4 Q30397595-5F3868F6-E55F-45DB-940B-45DF7F01AA97 Q30425594-9EE2F829-EB9D-4494-9807-32CC945D5F25 Q30537665-50343F13-483C-4E33-970B-EC7C6549C828 Q33592852-7C3571BF-C115-4CA4-9050-694426EEF4AC Q33594304-E290CB67-E291-448E-B5B5-C11C77BB04F7 Q33638320-EC717B1D-1B95-4ABF-B2B1-1099AF7FEEFB Q33680883-9CA860E3-DFDF-44C2-AF96-C353D89D9A99 Q33703451-0F69B869-E5F5-41FE-B22C-256C0E57CDD5 Q33719511-41CAF36B-2581-437C-87B4-D2AFFBE0DDF7 Q33764917-0CDE7627-99E0-4139-BE39-A0A543E88C8F Q33786447-85D61452-C69B-47C7-887E-598F775AF98D Q33798076-D23F84FB-492B-4506-9AAF-90B7ED92EBD8 Q33812812-7ED70AAE-D54D-4876-94BE-28725C27A617 Q33865785-3BDA685A-D535-4982-BC86-D5511AB9F526 Q33867353-0F5B6414-A3DB-415C-8D1A-AEC44A7BE637 Q33947008-2FEF54BC-D48E-4420-A22A-8626D9C20AD7 Q33955745-E8726145-7238-4DE9-BC94-1BAAE4B2EEED Q33957908-7DC0C5D3-322B-4AC0-BAFC-2A37C6D0ED88 Q34120140-BA1C3690-82BF-488C-AD4E-A10B4CA98BB9 Q34182086-BFCA495A-2551-4C89-9528-786DCE37A5D1 Q34300812-F0947AEF-844B-4BAE-B95F-0DEA41FA6D1B Q34389522-A3B85AE4-19C7-4B0F-820D-E5ADE09C4EAD

P2860

Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables

http://www.wikidata.org/entity/Q33614495

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Breadth of human immunodeficie ...... iation with clinical variables

@ast

Breadth of human immunodeficie ...... iation with clinical variables

@en

type

label

Breadth of human immunodeficie ...... iation with clinical variables

@ast

Breadth of human immunodeficie ...... iation with clinical variables

@en

prefLabel

Breadth of human immunodeficie ...... iation with clinical variables

@ast

Breadth of human immunodeficie ...... iation with clinical variables

@en

P1433

Q33614495-0895A2E1-4E47-4EF4-A89E-53B27FD9E01B

P1476

Q33614495-01B119D8-128D-4C30-903E-2C5E47F839BE

P2093

Q33614495-16A24BBC-E990-4C69-95D1-C5AC4AC79F1D

Q33614495-1A91DF3E-561B-4DB1-80B8-D323E80A3849

Q33614495-1D05F39B-F4F0-4202-B2E3-44102EFDD45F

Q33614495-4D888809-CCD7-4CDC-82C1-6D38438D40D2

Q33614495-72349D88-B51B-4CBD-B8B8-8E0B7BDE2751

Q33614495-8D581265-6BDC-45C2-B9FB-E7D38E75CB25

Q33614495-A629F587-60FF-46ED-B853-92F9B1AFCA3C

Q33614495-B3F1324E-A0A1-491D-9A95-66A09E821BA7

Q33614495-C7554D03-BAE4-4D0D-9B28-FE5F0423DA7B

P2860

Q33614495-0183FEBD-AB08-40F0-9FA7-6E0F2A307A8F

Q33614495-0EEDB8A9-027D-4884-9841-96870C04BF1D

Q33614495-188136EA-FA46-44A7-8C73-DF9D2B68B8CE

Q33614495-2CE686B8-E13B-4849-B716-5D1F65971492

Q33614495-346B0308-2C03-41E2-8AED-7203E6085299

Q33614495-498DE44C-0389-4D25-838D-09814CC6ED00

Q33614495-4C77588A-19F8-4CF0-AC5B-40621744EE13

Q33614495-56346C31-4627-4868-B986-B5C448F44CA2

Q33614495-56D3A244-BEA3-4544-90B2-12236DD89F5C

Q33614495-5F2BD792-5918-42F2-A719-CB295350D22D

P304

Q33614495-013F5903-8FC2-4228-AEEC-B82A1992AD47

P31

Q33614495-DE74793C-44F1-4974-B4BF-2597735E1A9C

P356

Q33614495-BB12BFA7-2E9E-4E81-84B5-B60309DE0284

P433

Q33614495-3E64D0E2-24FA-4276-B65B-A1DE565EDD30

P478

Q33614495-C70EFB53-1EEF-4286-B151-8C05CDC07870

P50

Q33614495-3D238A51-92A3-47B8-BC0E-2681A68A6C57

Q33614495-4C350851-83D5-488B-BB3C-9D462EC46285

Q33614495-595E54A0-9B36-4162-8DC3-C1AD1FF4DEE3

P577

Q33614495-284623A3-E7EF-4701-B739-B3AD548EE181

P5875

Q33614495-6F13221D-1999-4F17-A958-A50C5A8295D1

P698

Q33614495-06F57CE4-CCE2-4E47-8DDC-946842A72059

P932

Q33614495-BE66620A-72AF-4A16-BDFD-7DA5F71929C7

P356

P1433

Journal of Virology

P1476

Breadth of human immunodeficie ...... iation with clinical variables

@en

P2093

Alan Lapedes

http://www.w3.org/2001/XMLSchema#string

Marcus G Daniels

http://www.w3.org/2001/XMLSchema#string

Mark Connors

http://www.w3.org/2001/XMLSchema#string

Martha Nason

http://www.w3.org/2001/XMLSchema#string

Nicole A Doria-Rose

http://www.w3.org/2001/XMLSchema#string

Rachel M Klein

http://www.w3.org/2001/XMLSchema#string

Richard T Wyatt

http://www.w3.org/2001/XMLSchema#string

Sijy O'Dell

http://www.w3.org/2001/XMLSchema#string

Stephen A Migueles

http://www.w3.org/2001/XMLSchema#string

P2860

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

Clinical trials of HIV vaccines.

Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy.

B cells in HIV infection and disease

Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy.

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.

Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques

Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.

Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs

P304

1631-1636

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.01482-09

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

84

http://www.w3.org/2001/XMLSchema#string

P50

Tanmoy Bhattacharya

P577

2009-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38098911

http://www.w3.org/2001/XMLSchema#string

P698

19923174

http://www.w3.org/2001/XMLSchema#string

P932

2812355

http://www.w3.org/2001/XMLSchema#string